ASXC News and Press, Asensus Surgical Inc Com From 12/21/21

Reliance Global (NASDAQ:RELI) +85%. Aridis Pharmaceuticals (NASDAQ:ARDS) +72% after its antibody cocktail retains effectiveness against Omicron variant. Quoin Pharmaceuticals (NASDAQ:QNRX) +44%. Cassava Sciences (NASDAQ:SAVA) +40% Cassava Sciences, Biofrontera rise amid so...

RZD Medicine is the second Russian hospital to initiate a Senhance Surgical System program Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided S...

Franklin Medical Center to become 4th Senhance Hospital in Louisiana Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today ...

Surgical Robots market will grow at a rapid pace (CAGR of 20.1%) in the future. ASXC's Senhance System and other products are achieving regulatory clearances from U.S., Europe, and Asian authorities. More hospitals are buying or leasing their robots, and I expect the revenue growt...

3 Biotech Penny Stocks to Watch in Mid-November 2021 Biotech penny stocks remain some of the most popular stocks of the past year and a half. While the pandemic highlighted the biotech industry at first, we are still seeing the effects of this over one year after it began. But, not all ...

Shares of Asensus Surgical (NYSEMKT: ASXC) , a manufacturer of robot-assisted surgical systems, are on the rise after the company released third-quarter earnings. Investors reacting to the highlights drove the stock 14.6% higher as of 10:38 a.m. EDT on Thursday. After markets cl...

Asensus Surgical, Inc. (ASXC) Q3 2021 Earnings Conference Call November 03, 2021 4:30 PM ET Company Participants Mark Klausner - Westwicke, Investor Relations Anthony Fernando - President & Chief Executive Officer Shameze Rampertab - Chief Financial Officer Conference Call Participants Sw...

Shares of Asensus Surgical (NYSE:ASXC) are up 4% in after-hours trading after beating Q3 2021 analyst estimates on revenue and in-line on EPS. Net loss year-over-year increased ~7% to $15.1M (7 cents per common share). Revenue soared YoY 217% to $2.57M due to recent initiations of t...

Asensus Surgical (NYSE:ASXC): Q3 Non-GAAP EPS of -$0.06 in-line; GAAP EPS of -$0.07 misses by $0.01. Revenue of $2.57M (+217.3% Y/Y) beats by $1.55M. Shares -0.54%. Press Release The Company had cash, cash equivalents, short-term and long-term investments, excluding restricted cash of approxi...

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the third quarter 2021. R...